Gene Solutions Contributes Latest Prenatal Genomics Findings and Women’s Health Research at ISPD 2026
Gene Solutions will join the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD) as a Premier Partner, contributing an Industry Symposium, an Industry Scientific Session, and five selected oral and poster presentations, highlighting advances in integrated prenatal genomic screening and methylation-based gynecologic cancer risk assessment.
Gene Solutions is proud to participate in the 30th International Conference on Prenatal Diagnosis and Therapy, ISPD 2026, one of the leading global scientific forums dedicated to advancing reproductive medicine, prenatal diagnosis, fetal therapy, and maternal-fetal care.
Taking place from 7–9 July 2026, this landmark virtual conference will bring together clinicians, researchers, geneticists, fetal medicine specialists, laboratory experts, and healthcare innovators from around the world to exchange the latest scientific insights shaping the future of prenatal and reproductive healthcare.
At ISPD 2026, Gene Solutions will contribute to the scientific dialogue through a focused program of symposium discussions, scientific sessions, oral presentations, and virtual posters. Together, these contributions will spotlight two important directions in precision healthcare: next-generation non-invasive prenatal testing and methylation-based molecular triage for gynecologic cancers, anchored by innovations including triSure Procare, epiHERA®, and SPOT-MAS Eva.
Advancing Prenatal Screening Through Integrated Non-Invasive Testing
As prenatal care continues to evolve beyond conventional aneuploidy screening, there is growing clinical interest in more comprehensive, integrated approaches that can support earlier and more informed pregnancy management.
Gene Solutions will host an Industry Symposium titled:
Time: 7:30–8:30 EDT, 8 July 2026
Singapore Time: 7:30–8:30 PM
The symposium will bring together experts from the UK, Vietnam, Singapore, and the US to explore the clinical utility of integrated non-invasive prenatal testing, with a focus on expanded carrier screening, single-gene disorders, and AI-enabled risk stratification. [
Speakers include Ida Deleskog Lindstroem, Dr. Natalie Chandler, Dr. Sang Hung Tang, and Dr. Hoa Giang, who will share perspectives on responsible clinical integration of broader prenatal genomics, real-world evidence from Asian pregnant women, and multi-omic approaches for early pregnancy risk stratification.
Through this symposium, Gene Solutions aims to contribute to the ongoing discussion on how next-generation NIPT can move beyond traditional screening toward more comprehensive, evidence-based prenatal care.
Molecular Clarity in Gynecologic Care.
Gene Solutions will also support an Industry Scientific Session focused on minimally invasive molecular triage for endometrial cancer — a clinically important area where more precise risk assessment may help reduce unnecessary invasive procedures.
Time: 7:30–8:00 AM EDT, 9 July 2026
Singapore Time: 7:30–8:00 PM
The session will feature insights from Dr. Lee Ho Sze Jacqueline, Clinical Associate Professor at the Chinese University of Hong Kong, and Dr. Safedin Sajo Beqaj, Medical Laboratory Director at Gnosis, US, who will discuss the clinical validation and real-world application of the CDO1/CELF4 methylation assay, epiHERA®, as a minimally invasive molecular approach to support endometrial cancer risk assessment.
The discussion will focus on how methylation-based triage may help identify patients who require further invasive assessment while potentially reducing unnecessary dilation and curettage or biopsy procedures in selected high-risk populations.
This scientific direction is also reflected in SPOT-MAS Eva, Gene Solutions’ integrated gynecologic cancer screening and triage solution. SPOT-MAS Eva combines molecular assessment for cervical and endometrial cancers, including HPV genotyping and methylation-based analysis, within a single cervical swab workflow. By integrating molecular precision into a familiar sample collection method, SPOT-MAS Eva is designed to support clearer clinical decision-making and improve accessibility to advanced women’s cancer risk assessment.
Five ISPD-Selected Oral and Poster Presentations Highlighting Real-World Evidence in Prenatal Genomics
In addition to the Industry Symposium and Industry Scientific Session, Gene Solutions and Medical Genetics Institute Ho Chi Minh City will contribute five scientific abstracts, including two oral presentations and three virtual posters.
Oral Presentations
Time: 13:00–14:00 EDT, 7 July 2026
Format: 2 oral presentations
The oral presentations will share real-world evidence on expanded carrier screening and clinical exome sequencing, highlighting advances in prenatal genomic testing and their potential value in maternal-fetal medicine.
Topics include expanded carrier screening through routine NIPT in 225,092 Asian pregnant women, and the diagnostic yield of CNV-seq and clinical exome sequencing in 788 fetuses with fetal growth restriction.
Virtual Posters
Time: 13:30–14:15 EDT, 8 July 2026
Format: 3 virtual posters
The virtual posters will showcase research on thalassemia screening, NIPT clinical performance, and prenatal chromosomal abnormalities, contributing to the growing evidence base for genomic applications in prenatal care.
Together, these oral and poster presentations reinforce the value of real-world data from Asian populations and support continued advancement in prenatal genomic screening, clinical interpretation, and maternal-fetal medicine.
Strengthening Global Collaboration in Precision Reproductive and Women’s Health
As reproductive and women’s healthcare move toward earlier, more comprehensive, and more personalized approaches, collaboration between clinicians, researchers, laboratories, and healthcare innovators will be essential.
Gene Solutions’ participation at ISPD 2026 reflects the company’s broader commitment to translating genomic and epigenomic science into clinically meaningful solutions across the care continuum — from next-generation NIPT and expanded prenatal screening to methylation-based triage for gynecologic cancers.
By contributing data, clinical experience, and scientific perspectives at ISPD 2026, Gene Solutions aims to support a shared vision: empowering reproductive and women’s health through science, innovation, and collaboration.
Join Gene Solutions at ISPD 2026 to explore how integrated genomic and methylation-based technologies are helping shape the future of prenatal and women’s healthcare.
Learn more about ISPD 2026:
https://ispd2026.eventscribe.net/
https://www.ispdhome.org/ISPD/ISPD/Conference/2026_Conference.aspx
Discover triSure Procare: https://genesolutions.com/our-test/trisure-procare
Discover SPOT-MAS Eva: https://genesolutions.com/news/gene-solutions-expands-spot-mas-portfolio-with-accessible-cancer-screening-and-precision-triage-solutions
